AAAAAA

   
Results: 1-8 |
Results: 8
Dynamic stabilization in 1 sigma(u) -> 1 pi(g) excited nitrogen clusters
Authors: Flesch, R Pavlychev, AA Neville, JJ Blumberg, J Kuhlmann, M Tappe, W Senf, F Schwarzkopf, O Hitchcock, AP Ruhl, E
Citation: R. Flesch et al., Dynamic stabilization in 1 sigma(u) -> 1 pi(g) excited nitrogen clusters, PHYS REV L, 86(17), 2001, pp. 3767-3770
Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide
Authors: Kuhn, JM Arlot, S Lefebvre, H Caron, P Cortet-Rudelli, C Archambaud, F Chanson, P Tabarin, A Goth, MI Blumberg, J Catus, F Ispas, S Beck-Peccoz, P
Citation: Jm. Kuhn et al., Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide, J CLIN END, 85(4), 2000, pp. 1487-1491
Treatment of carcinoid syndrome - A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, andtolerance
Authors: O'Toole, D Ducreux, M Bommelaer, G Wemeau, JL Bouche, O Catus, F Blumberg, J Ruszniewski, P
Citation: D. O'Toole et al., Treatment of carcinoid syndrome - A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, andtolerance, CANCER, 88(4), 2000, pp. 770-776
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Authors: Ducreux, M Ruszniewski, P Chayvialle, JA Blumberg, J Cloarec, D Michel, H Raymond, JM Dupas, JL Gouerou, H Jian, R Genestin, E Hammel, P Rougier, P
Citation: M. Ducreux et al., The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors, AM J GASTRO, 95(11), 2000, pp. 3276-3281
Americans - "only female Medal of Honor recipient" (Dr. Mary Ewards!Walker)
Authors: Blumberg, J
Citation: J. Blumberg, Americans - "only female Medal of Honor recipient" (Dr. Mary Ewards!Walker), AM HIST, 34(4), 1999, pp. 20-20
A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study
Authors: Lhomme, C Vennin, P Callet, N Lesimple, T Achard, JL Chauvergne, J Luporsi, E Chinet-Charrot, P Coudert, B Couette, JE Guastalla, JP Lebrun, D Ispas, S Blumberg, J
Citation: C. Lhomme et al., A multicenter phase II study with triptorelin (sustained-release LHRH agonist) in advanced or recurrent endometrial carcinoma: A French Anticancer Federation study, GYNECOL ONC, 75(2), 1999, pp. 187-193
Vitamin E treatment of experimental glomerular disease in rats
Authors: Otani, H Mune, M Yukawa, S Smith, D Meydani, M Blumberg, J
Citation: H. Otani et al., Vitamin E treatment of experimental glomerular disease in rats, KIDNEY INT, 56, 1999, pp. S66-S69
Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruptionof treatment
Authors: Carel, JC Roger, M Ispas, S Tondu, F Lahlou, N Blumberg, J Chaussain, JL
Citation: Jc. Carel et al., Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruptionof treatment, J CLIN END, 84(6), 1999, pp. 1973-1978
Risultati: 1-8 |